{"product_id":"adarasib-adagrasib","title":"Adarasib (Adagrasib)","description":"\u003ch2\u003e\u003cspan id=\"About_Adagrasib\"\u003eAbout Adagrasib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eAdagrasib is a prescription medicine used in adults:\u003c\/p\u003e\u003cp\u003ealone to treat non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ethat has spread to other parts of the body or cannot be removed by surgery, and\u003c\/li\u003e\n\u003cli\u003ewhose tumor has an abnormal KRAS G12C gene, and\u003c\/li\u003e\n\u003cli\u003ewho have received at least one prior treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ein combination with a medicine called cetuximab to treat colon or rectal cancer (CRC)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ethat has spread to other parts of the body or cannot be removed by surgery, and\u003c\/li\u003e\n\u003cli\u003ewhose tumor has an abnormal KRAS G12C gene, and\u003c\/li\u003e\n\u003cli\u003ewho have previously received certain chemotherapy medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eYour healthcare provider will perform a test to make sure that Adagrasib is right for you.\u003c\/p\u003e\u003cp\u003eIt is not known if Adagrasib is safe and effective in children.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Non-Small_Cell_Lung_Cancer\"\u003eNon–Small Cell Lung Cancer\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults who have received ≥1 systemic treatment\u003c\/p\u003e\u003cp\u003e600 mg PO BID until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Colorectal_Cancer\"\u003eColorectal Cancer\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated in combination with cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer (CRC) in adults who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\u003c\/p\u003e\u003cp\u003e600 mg PO BID until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"In_a_clinical_trial_adagrasib_was_given_with_cetuximab\"\u003eIn a clinical trial, adagrasib was given with cetuximab\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003e500 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV q2wks, or\u003c\/li\u003e\n\u003cli\u003e400 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV once followed by 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV once weekly\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h2\u003e\u003ch3\u003e\u003cspan id=\"Dosage_reductions_for_adverse_reactions\"\u003eDosage reductions for adverse reactions\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 400 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 600 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 600 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Nausea_or_vomiting\"\u003eNausea or vomiting\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4 despite providing supportive care (eg, antiemetic therapy)\u003c\/li\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Diarrhea\"\u003eDiarrhea\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4 despite providing supportive care (eg, antidiarrheal therapy)\u003c\/li\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"QT_interval_prolongation\"\u003eQT interval prolongation\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch4\u003e\u003cspan id=\"Corrected_QT_QTc_absolute_value_500_msec_OR_an_increase_60_msec_from_baseline\"\u003eCorrected QT (QTc) absolute value \u0026gt;500 msec OR an increase \u0026gt;60 msec from baseline\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until QTc \u0026lt;481 msec or return to baseline\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eTorsade de pointes\u003c\/li\u003e\n\u003cli\u003ePolymorphic ventricular tachycardia\u003c\/li\u003e\n\u003cli\u003eSigns or symptoms of serious or life-threatening arrhythmia\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatotoxicity\"\u003eHepatotoxicity\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 2 AST\/ALT: Decrease to next lower dose level\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003e\u003cspan id=\"Grade_3_or_4_ASTALT\"\u003eGrade 3 or 4 AST\/ALT\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003e\u003cspan id=\"Permanently_discontinue1\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003eAST\/ALT \u0026gt;3x ULN with total bilirubin \u0026gt;2x ULN in the absence of alternative causes\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Interstitial_lung_disease_ILD_or_pneumonitis_any_grade\"\u003eInterstitial lung disease (ILD) or pneumonitis (any grade)\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eSuspected ILD\/pneumonitis: Withhold therapy\u003c\/li\u003e\n\u003cli\u003eConfirmed ILD\/pneumonitis: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\u003cli\u003e\n\u003ch4\u003e\u003cspan id=\"Grade_3_or_4\"\u003eGrade 3 or 4\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold therapy until Grade ≤1 or return to baseline\u003c\/li\u003e\n\u003cli\u003eResume therapy at next lower dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\u003cli\u003eMild to severe (CrCl 15 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\u003cli\u003eMild to severe (Child-Pugh A to C): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h2\u003e\u003ch3\u003e\u003cspan id=\"Monitoring_Parameters\"\u003eMonitoring Parameters\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMonitor ECGs and electrolytes before initiating, during treatment, and as clinically indicated in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, and in patients who are unable to avoid drugs known to prolong the QT interval\u003c\/li\u003e\n\u003cli\u003eMonitor AST, ALT, alkaline phosphatase, and total bilirubin before initiating and monthly for 3 months or as clinically indicated; perform more frequent testing in patients who develop transaminase elevations\u003c\/li\u003e\n\u003cli\u003eMonitor for new or worsening respiratory symptoms (eg, dyspnea, cough, fever) during treatment\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797957537835,"sku":"RL3320250303","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-03-0242.png?v=1787022287","url":"https:\/\/xomeds.com\/products\/adarasib-adagrasib","provider":"XOMEDS","version":"1.0","type":"link"}